Search Results

Zafgen, Inc. (Nasdaq:ZFGN) today reported its fourth quarter and full year 2019 financial results.

Zafgen, Inc. (Nasdaq:ZFGN) today reported its third quarter 2019 financial results.

Shares of Zafgen are down more than 22 percent in premarket trading after the company announced Monday that it was suspending plans to develop a treatment for Prader-Willi syndrome.

Shares of Boston-based Zafgen, Inc. plunged more than 32 percent in pre-market trading after the company announced the U.S. Food and Drug Administration has slapped a clinical hold on its plans to launch a clinical trial in the United States for an experimental diabetes medicine due to safety concerns.

- Shares of combined company to commence trading on Nasdaq Global Market under the symbol “LRMR” on May 29, 2020 - Company signed $80 million in private placement financing with biotechnology focused institutional investors - New Board Chair, Chief Medical Officer and Chief Financial Officer appointed BALA CYNWYD, Pa., May 29, 2020 (GLOBE NEWSWIRE) -- Chondrial Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today ann

Creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases

SwanBio Therapeutics (SwanBio), a gene therapy company advancing AAV-based therapies for the treatment of devastating, genetically defined neurological conditions, today announced the appointments of Patricia “Patty” Allen, former Chief Financial Officer of Zafgen, Inc.; Danny Bar-Zohar, M.D., Global Head of Development at Merck KGaA; and Alex Hamilton, Ph.D., Partner at Syncona, to the company’s Board of Directors

The company will be returning to rare disorders with ZGN-1258.